The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
Jul 31, 2018 - 00:24:45
Radio and PodcastLive Radio & PodcastsHealth
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
The FDA announced that a review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly mo...
About This Episode
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk is an episode from FDA Drug Information Updates by ReachMD. The FDA announced that a review of four large clinical safety trials shows th...
Podcast
This episode belongs to FDA Drug Information Updates.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Jan 4, 2018, 00:03:00 long, audio available.
Related Episodes
Continue listening to more episodes from FDA Drug Information Updates.
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
May 4, 2018 - 00:02:59
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Jan 7, 2018 - 00:08:29
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
Jan 5, 2018 - 00:02:59
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
Oct 29, 2017 - 00:09:22
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
Aug 17, 2017 - 00:05:29
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
Jul 28, 2017 - 00:06:00
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
Jul 25, 2017 - 00:09:00
Questions About This Episode
What is FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk about?
The FDA announced that a review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone. A link to the full communication detailing information for health care professionals and the Data Summary can be found at . Released 12/20/2017
Where can I listen to FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk?
You can listen to FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk from?
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk is an episode from FDA Drug Information Updates by ReachMD.
How long is this episode?
This episode is 00:03:00 long.
When was this episode published?
This episode was published on Jan 4, 2018.
Can I save FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from FDA Drug Information Updates?
Yes. This page shows related episodes from FDA Drug Information Updates when more episodes are available from the podcast feed.